



Altimmune to Participate at Two Upcoming Investor Conferences

November 6, 2024 at 7:30 AM EST

GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- [Altimmune, Inc.](#) (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in the following investor conferences:

- **Guggenheim Inaugural Healthcare Innovation Conference** (Boston, MA)
Monday, November 11, 2024
Fireside Chat at 11:30 a.m. Eastern Time
- **UBS Global Healthcare Conference** (Rancho Palos Verdes, CA)
Wednesday, November 13, 2024
Available for 1x1 meetings
Fireside Chat at 9:30 a.m. Pacific Time

The sessions will be webcast and can be accessed by visiting the [Events](#) section of the Altimmune website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on [LinkedIn](#)

Follow @AltimmuneInc on [Twitter](#)

Company Contact:

Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
ir@altimmune.com

Media Contact:

Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com

Investor Contacts:

Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

This press release was published by a CLEAR® Verified individual.



Source: Altimmune, Inc